About Us
Pharmakon Advisors, LP (“Pharmakon”) is the investment manager of the BioPharma Credit funds. Established in 2009, Pharmakon has raised a total of US$4.9 billion, principally across five private funds and a publicly traded UK Trust. BioPharma Credit PLC (ticker: BPCR.L “BPCR”) was listed on the London Stock Exchange in March 2017 and has raised a total of $1.4 billion in capital. Pharmakon has committed US$9.8 billion across 57 investments in companies in the life sciences.
Senior Management
Pedro Gonzalez de Cosio
Co-Founder, Principal and CEO
Pedro Gonzalez de Cosio
Co-Founder, Principal and CEO
Mr. Gonzalez de Cosio is a Principal and co-founder of Pharmakon Advisors and manages the company’s portfolio. During the 14 years prior to founding Pharmakon Advisors, Mr. Gonzalez de Cosio held various positions in structured finance divisions of Deutsche Bank and JP Morgan in New York where he was responsible for structuring various forms of collateralized financings and derivatives for U.S. and international clients, including several years covering clients in the Biotech and Pharmaceutical industries. Mr. Gonzalez de Cosio’s prior experience also includes various positions at the investment banking division of Nomura Securities in New York, the leasing division of Société Géneralé in Paris, and coordinating the issuance of external debt for the Mexican Ministry of Finance. Mr. Gonzalez de Cosio earned a B.A. degree (Summa Cum Laude) in Business Administration from the University of San Diego and an M.B.A. from INSEAD in Fontainebleau, France.
Pablo Legorreta
Co-Founder and Principal
Pablo Legorreta
Co-Founder and Principal
Mr. Legorreta is co-founder and Chief Executive Officer of Royalty Pharma and a Principal and co- founder of Pharmakon Advisors providing advisory oversight. Founded in 1996, Royalty Pharma is a leading investor in pharmaceutical royalties. Prior to founding Royalty Pharma, Mr. Legorreta had a ten-year career in investment banking with Lazard Frères in Paris and New York. Mr. Legorreta earned a degree in Industrial Engineering from Universidad Iberoamericana in Mexico City, Mexico.
Martin Friedman
Principal
Martin Friedman
Principal
Mr. Friedman is a Principal of Pharmakon Advisors, having joined in 2011. Prior to joining Pharmakon Advisors, Mr. Friedman has worked in various positions in the Health Care Finance industry most recently as the Co-Head of Life Sciences banking at Bank of America/Merrill Lynch for 3 years. He has worked very closely with both large cap and emerging Pharma, Biotech, Specialty Pharma, Device and Diagnostic companies having advised on M&A transactions and raised equity and debt capital. Mr. Friedman’s prior experience also includes 12 years at JP Morgan including 4 years at JP Morgan Partners and several years as the Head of M&A and Collaborations at Novartis AG based in Switzerland. Mr. Friedman earned a B.A. degree in English and History from Columbia College and an M.B.A. (Honors) in Finance and Accounting from Columbia Business School.
Major Transactions
Click on a transaction in order to view the corresponding press release.*
May 2024
$400,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
April 2024
$200,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
May 2023
$275,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
April 2023
$450,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
April 2023
$125,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
November 2022
$100,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
October 2022
$350,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
March 2022
$200,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
February 2022
$650,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
January 2022
$300,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
December 2021
$125,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
March 2021
$300,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
February 2020
$200,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
December 2019
$250,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
December 2019
$550,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
November 2019
$100,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
November 2019
$220,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-V
September 2019
$150,000,000
Senior Secured Note
Sole Lender
BioPharma PLC & BioPharma-V
May 2019
$80,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC
September 2018
$150,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC
May 2018
$315,000,000
Senior Secured Loan
Lead
BioPharma PLC
February 2018
$150,000,000
Structured Royalty Investment
Sole Lender
BioPharma PLC
December 2017
$150,000,000
Structured Royalty Investment
Marketer
Product
Co-Investor
BioPharma PLC
December 2017
$200,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-IV
November 2017
$500,000,000
Senior Secured Loan
Sole Lender
BioPharma PLC & BioPharma-IV
September 2017
$50,000,000
Corporate Loan
Sole Lender
BioPharma-IV
November 2016
Undisclosed
Capped Royalty
Marketer
Product
Sole Purchaser
BioPharma-IV
January 2016
$150,000,000
Royalty Backed Loan
Marketer
Product
Lead
BioPharma-IV
December 2015
$175,000,000
Senior Secured Loan
Lead
BioPharma-IV
November 2015
$55,000,000
Senior Secured Loan
Sole Lender
BioPharma-III
March 2015
$575,000,000
Senior Secured Loan
Lead
BioPharma-III
December 2013
$30,000,000
Senior Secured Loan
Marketer
Product
Sole Lender
BioPharma-III
December 2012
$100,000,000
Capped Royalty
Marketer
Product
Sole Purchaser
BioPharma-II
November 2012
$30,000,000
Royalty Backed Loan
Marketer
Product
Sole Purchaser
BioPharma-II
August 2012
$30,000,000
Capped Royalty
Marketer
Product
Sole Purchaser
BioPharma-II
August 2012
$78,000,000
Capped Royalty
Marketer
Product
Sole Purchaser
BioPharma-II
June 2010
$100,000,000
Royalty Backed Notes
Marketer
Product
Sole Purchaser
BioPharma-I
September 2009
$132,000,000
Royalty Backed Notes
Marketer
Product
Sole Purchaser
BioPharma-I
Press Releases
Latest press releases. Click on a press release to view it in a new window.*